TC Biopharm (Holdings) (TCBPY) AI Stock Analysis

• Market Cap: $63.83K
• Dividend Yield: N/A
• Average Volume (3M): 8.91K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,103,054
• 10 Day Avg. Volume: 7,787
• 30 Day Avg. Volume: 8,914
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: ―

TC Biopharm's overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock's financial instability and operational inefficiencies are major concerns.

Positive Factors

Innovative Product Pipeline

TC Biopharm's focus on gamma-delta T cell technology positions it at the forefront of innovative cancer treatments, offering potential long-term growth through successful product development and commercialization.

Strategic Partnerships

Strategic partnerships with larger pharmaceutical firms provide TC Biopharm with financial support and market access, enhancing its ability to bring therapies to market and generate sustainable revenue.

Equity Improvement

Improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future financial stability and growth.

Negative Factors

Declining Revenues

A significant decline in revenue indicates challenges in product commercialization and market penetration, posing risks to long-term financial viability and growth prospects.

Negative Cash Flow

Persistent negative cash flow from operations suggests difficulties in sustaining business activities without external financing, impacting long-term operational sustainability.

High Debt Levels

High debt levels can strain financial resources, limiting flexibility and increasing risk, which could hinder the company's ability to invest in growth opportunities and weather economic downturns.

TC Biopharm (Holdings) Business Overview & Revenue Model

Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

How the Company Makes Money

TC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop or distribute its therapies, thereby receiving upfront payments, milestone payments, and royalties on sales. Additionally, TC Biopharm may engage in research collaborations or receive grants and funding from governmental or non-governmental organizations to support its research and development activities. The success of its revenue model relies heavily on the successful advancement of its therapies through clinical trials and regulatory approval processes.

TC Biopharm (Holdings) Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

TC Biopharm (Holdings) Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCBPY, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.12, and below the 200-day MA of 0.25, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 48.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCBPY.

TC Biopharm (Holdings) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	44 Neutral	$2.36M	-0.11	-203.36%	―	―	90.53%
SCNI	43 Neutral	$737.84K	-0.07	―	―	178.82%	-4121.10%
TCBPY	38 Underperform	$63.83K	―	―	―	―	―

TC Biopharm (Holdings) Corporate Events

TC BioPharm Appoints Interim Liquidators Amid Deregistration Plans

On November 10, 2025, TC BioPharm (Holdings) plc announced the appointment of Ben Cairns and Michael Magnay from Alvarez and Marsal Europe LLP as interim liquidators. This decision marks a significant shift in the company’s operations, as it plans to deregister its American Depositary Shares and suspend its obligation to file periodic reports with the SEC. This move indicates a potential winding down of operations, which could have considerable implications for stakeholders and the company’s market positioning.

The most recent analyst rating on (TCBPY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on TC Biopharm (Holdings) stock, see the TCBPY Stock Forecast page.

TC BioPharm Limited Enters Administration Amid Asset Sale Exploration

On October 2, 2025, TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) plc, entered administration with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP appointed as joint administrators. They are exploring options for the sale of the business and assets, including intellectual property and R&D assets, to benefit creditors. Despite this development, TC BioPharm (Holdings) plc continues its operations unaffected by the administration process, maintaining its industry positioning and commitment to its stakeholders.

The most recent analyst rating on (TCBPY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on TC Biopharm (Holdings) stock, see the TCBPY Stock Forecast page.